Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva\u2019s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments.<\/p>\n\n\n\n
[\u2026]<\/p>\n\n\n\n
\u201cThe proceeds will be used to fund continued development of roluperidone, the Company\u2019s proprietary lead compound, which is in Phase 3 development to treat negative symptoms in schizophrenia.\u201d \u201cWe are delighted to partner with Minerva,\u201d said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.<\/p>\n\n\n\n
[\u2026]<\/p>\n\n\n\n
Cooley acted as legal advisors to Minerva Neurosciences on the transaction. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma on the transaction.<\/p>\n\n\n\n
This text is a press release from Royalty Pharma. The full text version of the article can be found here: Royalty Pharma Acquires Royalty Interest in Seltorexant from Minerva Neurosciences \u2013 Royalty Pharma<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2145","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/2145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/presseberichte\/2145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=2145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}